NASA is set to send astronauts around the Moon again

NASA reports accelerated progress across human spaceflight, science missions and advanced technology in the first year of the current administration, completing two crewed missions, launching 15 science missions and test-flying a new X-plane, with Artemis II planned to send astronauts around the Moon and a return to lunar surface targeted by 2028. Policy and funding support cited (National Space Policy, Working Families Tax Cut Act) plus advances in nuclear propulsion and the Nancy Grace Roman Space Telescope point to sustained government-driven demand for aerospace, defense and technology contractors supplying launch services, propulsion, and deep-space systems.

Analysis

Market structure: NASA’s renewed Artemis push and explicit funding signals (near-term appropriations + multi-year program guidance) tilt demand toward large aerospace & defense primes (LMT, NOC, RTX) and specialist suppliers (MAXR, BWXT) for at least the next 2–5 years. Commercial aerospace (BA) and small-cap consumer space plays (SPCE) face asymmetric risk: program-driven revenue is concentrated in defense primes while commercial cycles remain weak, concentrating pricing power with contractors that hold prime contracts and IP.

Risk assessment: Key tail risks are program delays/catastrophic test failure or a change in congressional funding (20–40% budget swing risk in adverse scenarios) that would compress contractor free cash flow and equity multiples; supply-chain bottlenecks (titanium/rare earths, specialist engines) could push capex and margins higher in 6–24 months. Hidden dependency: sustained returns rely on continued political support and steady NASA contract awards—watch FY2027 appropriations and export-control shifts as binary catalysts.

Trade implications: Overweight large primes and select suppliers for 12–36 month horizon; use defined-risk options to express convexity around budget approvals and Artemis milestones (launch windows, test completions). Rotate out of pure-play space tourism and long-duration Treasuries (expect incremental deficit issuance); metals and specialty manufacturing suppliers are tactical buys on any pullbacks.

Contrarian angles: Consensus underprices program execution risk and post-Apollo drawdown precedent—market may be overenthusiastic on perpetual growth expectations for smaller space names while underestimating how consolidation shifts margins to primes. A successful Artemis II will re-rate primes but a high-profile failure or budget cut would hit small caps hardest and likely create 20–50% dislocations in select names within weeks.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Lockheed Martin (LMT) and a 2% long in Northrop Grumman (NOC) over the next 30–60 days; target 12–24 month upside of 15–30% given program routing and steady FCF; hard stop-loss at -12%.
• Initiate a pair trade: long 2% LMT vs short 1.5% Boeing (BA) to capture relative defense allocation upside vs commercial execution risk over a 6–12 month horizon; rebalance after any major Artemis test milestone or FAA/BA news.
• Buy defined-risk options for convex exposure: purchase NOC Jan 2028 10% OTM LEAP call spread (buy calls ~10% OTM, sell ~30% OTM) sized to risk 1% of portfolio—holds through key FY2027 budget decisions and Artemis II completion.
• Reduce long-duration Treasury ETF (TLT) exposure by ~25% within 30 days and redeploy proceeds (half) into A&D equities above and (half) into BWXT (BWXT) 1–2% position for 24–36 month exposure to nuclear power/propulsion demand; monitor FY2027 appropriations and Artemis launch dates as re-entry/trim signals.